Ashley N Brown

List of Publications by Year
in descending order

24 papers	668 citations	687363 13 h-index	642732 23 g-index
24 all docs	24 docs citations	24 times ranked	1145 citing authors

#	Article	IF	Citations
1	UV-4B potently inhibits replication of multiple SARS-CoV-2 strains in clinically relevant human cell lines. Frontiers in Bioscience, 2022, 27, 1.	2.1	4
2	Combination Regimens of Favipiravir Plus Interferon Alpha Inhibit Chikungunya Virus Replication in Clinically Relevant Human Cell Lines. Microorganisms, 2021, 9, 307.	3.6	7
3	Antiviral Activity of the PropylamylatinTM Formula against the Novel Coronavirus SARS-CoV-2 In Vitro Using Direct Injection and Gas Assays in Virus Suspensions. Viruses, 2021, 13, 415.	3.3	5
4	Antiviral Evaluation of UV-4B and Interferon-Alpha Combination Regimens against Dengue Virus. Viruses, 2021, 13, 771.	3.3	7
5	1088. A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment of Coronavirus Disease (COVID-19). Open Forum Infectious Diseases, 2021, 8, S635-S635.	0.9	2
6	Modeling the viral dynamics of SARS-CoV-2 infection. Mathematical Biosciences, 2020, 328, 108438.	1.9	120
7	Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system. European Journal of Pharmaceutical Sciences, 2018, 111, 443-449.	4.0	34
8	Zika Virus Replication Is Substantially Inhibited by Novel Favipiravir and Interferon Alpha Combination Regimens. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	29
9	Antiviral Effects of Clinically-Relevant Interferon-Î± and Ribavirin Regimens against Dengue Virus in the Hollow Fiber Infection Model (HFIM). Viruses, 2018, 10, 317.	3.3	18
10	The effectiveness of antiviral agents with broad-spectrum activity against chikungunya virus varies between host cell lines. Antiviral Chemistry and Chemotherapy, 2018, 26, 204020661880758.	0.6	37
11	A sensitive electrochemical immunosensor for label-free detection of Zika-virus protein. Scientific Reports, 2018, 8, 9700.	3.3	148
12	Clinical Regimens of Favipiravir Inhibit Zika Virus Replication in the Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	19
13	Utility of a Novel Three-Dimensional and Dynamic (3DD) Cell Culture System for PK/PD Studies: Evaluation of a Triple Combination Therapy at Overcoming Anti-HER2 Treatment Resistance in Breast Cancer. Frontiers in Pharmacology, 2018, 9, 403.	3.5	8
14	Searching for synergy: Identifying optimal antiviral combination therapy using Hepatitis C virus (HCV) agents in a replicon system. Antiviral Research, 2017, 146, 149-152.	4.1	5
15	Application of pharmacometrics and quantitative systems pharmacology to cancer therapy: The example of luminal a breast cancer. Pharmacological Research, 2017, 124, 20-33.	7.1	13
16	Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV). Scientific Reports, 2017, 7, 14421.	3.3	6
17	Reply to Scagnolari et al.. Journal of Infectious Diseases, 2016, 215, jiw580.	4.0	0
18	Chikungunya Virus: In Vitro Response to Combination Therapy With Ribavirin and Interferon Alfa 2a. Journal of Infectious Diseases, 2016, 214, 1192-1197.	4.0	45

#	Article	IF	Citations
19	Pharmacokinetic Determinants of Virological Response to Raltegravir in theIn VitroPharmacodynamic Hollow-Fiber Infection Model System. Antimicrobial Agents and Chemotherapy, 2015, 59, 3771-3777.	3.2	13
20	Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy. MBio, 2015, 6, e01741-15.	4.1	60
21	Pharmacodynamic Analysis of a Serine Protease Inhibitor, MK-4519, against Hepatitis C Virus Using a NovelIn VitroPharmacodynamic System. Antimicrobial Agents and Chemotherapy, 2012, 56, 1170-1181.	3.2	12
22	Effect of Half-Life on the Pharmacodynamic Index of Zanamivir against Influenza Virus Delineated by a Mathematical Model. Antimicrobial Agents and Chemotherapy, 2011, 55, 1747-1753.	3.2	27
23	Zanamivir, at 600 Milligrams Twice Daily, Inhibits Oseltamivir-Resistant 2009 Pandemic H1N1 Influenza Virus in an In Vitro Hollow-Fiber Infection Model System. Antimicrobial Agents and Chemotherapy, 2011, 55, 1740-1746.	3.2	24
24	In Vitro System for Modeling Influenza A Virus Resistance under Drug Pressure. Antimicrobial Agents and Chemotherapy, 2010, 54, 3442-3450.	3.2	25